Skip to Content

Notice

Prospective Grant of Exclusive Patent License

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

National Institute of Standards and Technology, Department of Commerce.

ACTION:

Notice; prospective grant of exclusive patent license.

SUMMARY:

The National Institute of Standards and Technology (“NIST”), U.S. Department of Commerce, is contemplating the grant of an exclusive license in the United States of America, its territories, possessions and commonwealths, to NIST's interest in the invention embodied in U.S. Patent Application No. 62/302,855, titled “Prostate Cancer Detection Using Western Blot Analysis,” (NIST Docket No. 16-007) to McJimpsey Biotechnologies, Inc. The grant of the license would be for prostate cancer detection.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Donald Archer, National Institute of Standards and Technology, Technology Partnerships Office, 100 Bureau Drive, Stop 2200, Gaithersburg, MD 20899, (301) 975-2522; donald.archer@nist.gov.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within fifteen (15) days from the date of this published Notice, NIST receives written evidence and argument which establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. The Provisional Patent Application was filed on March 3, 2016 and describes systems and methods for detecting prostate cancer.

Start Signature

Phillip Singerman,

Associate Director for Innovations and Industry Services.

End Signature End Supplemental Information

[FR Doc. 2017-06003 Filed 3-24-17; 8:45 am]

BILLING CODE 3510-13-P